Go to deals
Healthcare

Time-Cap Labs, Inc. has been acquired by Marksans Pharma Ltd.

The founder and owner of Time-Cap Labs, Inc. has sold the company to Marksans Pharma Limited for an undisclosed consideration.

Founded in 1978 and based in Farmingdale, New York, Time-Cap Labs, Inc. manufactures and supplies generic pharmaceuticals and over-the-counter drugs. The company specializes in delayed and sustained release dosages. It offers various formulations, including analgesics, laxatives, dietary supplements, cough and cold medications, prescription drugs, antacids, and other products. The company offers its products to large and small wholesalers and distributors.

Marksans Pharma Limited, together with its subsidiaries, is engaged in the research, manufacture, and marketing of generic pharmaceutical formulations worldwide. Its product portfolio covers primary therapeutic segments of CVS, analgesics, decongestants, gastrointestinal, cardiovascular, anti-diabetics, central nervous system, oncology, anti-allergic drugs, and others. It also manufactures and distributes over-the-counter pharmaceutical products in the areas of cough and cold remedies, galenicals, vitamins, palliative and healthcare items, oils, antiseptics, and disinfectants; and offers contract research and manufacturing services to global pharmaceutical companies. Marksans Pharma Limited is headquartered in Mumbai, India.

One of Oaklins' teams in the USA served as the exclusive financial advisor to the seller in this transaction.

Parties

Talk to the deal team

Paul R. Smolevitz

Managing Director
New York, United States
Oaklins TM Capital

James McLaren

Managing Director
New York, United States
Oaklins TM Capital

Vidur Kapur

Associate Director
New York, United States
Oaklins TM Capital

Related deals

Xiel Limited has been acquired by MIS Healthcare
Private Equity | Healthcare

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Learn more
Bayer AG has entered into a takeover agreement with Cara Care
Healthcare | TMT

Bayer AG has entered into a takeover agreement with Cara Care

Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Learn more
Saideep Healthcare and Research has raised equity
Healthcare

Saideep Healthcare and Research has raised equity

Saideep Healthcare and Research Private Limited has successfully completed a fundraising. This funding will help Saideep become a leading healthcare brand, offering advanced specialties across the region. The funds from this collaboration will be used to diversify into new and complex specialties, expand infrastructure and meet the growing demand for high-quality healthcare services in Western India.

Learn more